Sonnet BioTherapeutics Holdings, Inc. submits 10-K to SEC: Key Details.
Sonnet BioTherapeutics Holdings, Inc. has submitted its Form 10-K annual report to the Securities and Exchange Commission. This filing provides a comprehensive overview of the company’s financial performance, operations, and risk factors. With 81 documents included in the submission, investors and stakeholders can gain valuable insights into Sonnet BioTherapeutics’ activities and future outlook.
Attachments:
1. Link to Form 10-K Document
2. Link to EX-4.8 Document
3. Link to EX-19.1 Document
Additional information:
– Sonnet BioTherapeutics is a pharmaceutical company based in Princeton, NJ, focusing on the development of innovative therapies for various medical conditions.
– The company’s Fiscal Year End is on September 30th.
– For further details, the complete submission text file can be accessed here.
– Contact information: Business Address – 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540, Phone: 609-375-2227.
For a more in-depth review of Sonnet BioTherapeutics Holdings, Inc.’s performance and future prospects, interested parties can refer to the original SEC filing here.
